WHICH HEMATOLOGIC PARAMETERS PREDICT SURVIVAL IN PATIENTS WITH SMALL CELL LUNG CANCER?

YERSAL, Özlem; Dönmez Yalçın, Gizem; oktay, esin; Nayir, Erdinc; Meydan, Nezih; KESKIN, Ozge; EYİLER, M. Ferhat; Tanriverdi, Ozgur

WHICH HEMATOLOGIC PARAMETERS PREDICT SURVIVAL IN PATIENTS WITH SMALL CELL LUNG CANCER?

Esin OKTAY, (Adnan Menderes Üniversitesi, Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı, Aydın, Türkiye)

Ozge KESKIN, (Selçuk Üniversitesi, Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı, Konya, Türkiye)

M. Ferhat EYİLER, (Aydın Atatürk Devlet Hastanesi, Radyasyon Onkolojisi Bölümü, Aydın, Türkiye)

Özlem YERSAL, (Adnan Menderes Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Tıbbi Onkoloji Bilim Dalı, Aydın, Türkiye)

Özgür TANRIVERDİ, (Muğla Sıtkı Koçman Üniversitesi, Tıp Fakültesi, İç Hastalıkları Tıbbi Onkoloji Bilim Dalı, Muğla, Türkiye)

Erdinç NAYIR, (Kahramanmaraş Devlet Hastanesi, Tıbbi Onkoloji Bölümü, Kahramanmaraş, Türkiye)

Gizem DÖNMEZ YALÇIN, (Adnan Menderes Üniversitesi, Tıp Fakültesi, Tıbbi Biyoloji Anabilim Dalı, Aydın, Türkiye)

Nezih MEYDAN (Adnan Menderes Üniversitesi Tıp Fakültesi Tıbbi Onkoloji Bilim Dalı, Aydın, Türkiye)

İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi

2 0

Yıl: 2019 Cilt: 23 Sayı: 1 Sayfa Aralığı: 61 - 70 Metin Dili: İngilizce İndeks Tarihi: 24-10-2019

WHICH HEMATOLOGIC PARAMETERS PREDICT SURVIVAL IN PATIENTS WITH SMALL CELL LUNG CANCER?

Öz:

Introduction : Small cell lung cancer(SCLC) is the most aggressive form of lung cancer. Recent studies showedthat inflammation plays an important role in carcinogenesis. In this study, we investigated the survival impact ofpre-treatment multiple inflammatory and hematological blood parameters and their relation between each other inSCLC.Material and Method: This retrospective study enrolled 110 SCLC patients. The patients underwent platinumbased combination chemotherapy as a first-line treatment between 2012-2015. Untreated patients' hematologicaltests were taken into evaluation at initial diagnosis. Neutrophil, lymphocyte, platelet, hemoglobin (HGB), meancorpuscular volume (MCV), and mean platelet volume (MPV) values were collected. neutrophil-lymphocyte ratio(NLR)and the platelet-lymphocyte ratio (PLR), immune-inflammation index (SII) were calculated. Overall survivalof patients (OS) was calculated until to January 2017. All analyses were conducted by SPSS v23.0 statisticalsoftware.Results: Favorable prognostic factors were found to be age ˂65 years, limited stage, presence of curativeradyotherapy and good performans status. In univariate analysis showed that neutrophil-lymphocyte ratio(NLR)<5, and mean corpuscular volume (MCV)>85 fl predicted better survival outcomes in extensive-stage SCLCpatients. In our study; patients at extensive-stage with platelet-lymphocyte ratio(PLR)<250 or systemic immuneinflammation index (SII)<1,600x109/L had longer overall survival (OS) but statistical significance could not beachieved. COX regression analyses showed that age (≥65 years), NLR≥5, and MCV≤85 fl were independentunfavorable prognostic factors for OS in extensive-stage. However mean platelet volume(MPV), MPV/plateletratio and hemoglobin have no effect on survival in all stage SCLC patients.Conclusion: Our study demonstrates that NLR and MCV could help to predict poor prognosis in extensive-stage,treatment naive SCLC patients. Nevertheless prospective studies are needed to confirm these results.

Anahtar Kelime:

Konular: Genel ve Dahili Tıp

KÜÇÜK HÜCRELİ AKCİĞER KANSERİ HASTALARINDA HANGİ HEMATOLOJİK PARAMETRELER YAŞAM SÜRESİNİN BELİRTEÇLERİDİR?

Öz:

Giriş: Küçük hücreli akciğer kanseri(KHAK) akciğer kanserleri arasında en agresif türdür. İnflamasyonun bir çok kanser türünün gelişmesi ve progresyonunda kritik rol aldığı gösterilmiştir. Bu çalışmada KHAK’i hastalarında tedavi öncesi inflamasyon ile ilgili skorların ve hematolojik parametrelerin sağkalım için prognostik değeri incelenmiştir. Gereç ve Yöntem: KHAK’i tanılı 110 olgunun tedavi öncesi klinik ve hematolojik verileri retrospektif olarak incelendi. 2012-2015 yılları arasında birinci basamak tedavide platin bazlı kombinasyon kemoterapisi uygulanan hastaların tanı anında tedavi öncesi hematolojik testleri değerlendirildi. Nötrofil, lenfosit, trombosit, hemoglobin (HGB), ortalama korpusküler hacim (MCV) ve ortalama trombosit hacmi (MPV) değerleri toplandı. Nötrofil lenfosit oranı (NLR) ve trombosit-lenfosit oranı (PLR), immün inflamasyon indeksi (SII) hesaplandı. Hastaların genel sağkalımı Ocak 2017'ye kadar hesaplandı. Tüm analizler SPSS v23.0 istatistik yazılımı ile yapıldı. Bulgular: Tüm hastalardaki yaşam süresi analizinde iyi prognostik kriter; ˂65 yaş, sınırlı evre, küratif radyoterapi varlığı ve iyi performans durumu olarak tesbit edildi. Tek değişkenli analizde yaygın evre KHAK hastalarında, nötrofil lenfosit oranı (NLR) <5 ve ortalama korpuskülar volüm (MCV)> 85 fl ise sağkalım sonuçlarının daha iyi olduğu gösterilmiştir. Çalışmamızda; trombosit-lenfosit oranı (PLR) <250 olan veya sistemik immün inflamasyon indeksi (SII) <1,600x109 / L olan yaygın evredeki hastalarda genel sağkalım(OS) daha uzundu ancak istatistiksel olarak anlamlı değildi. COX regresyon analizinde, yaş(≥65 yaş), NLR≥5 ve MCV≤85 fl'nin yaygın evre hastalıkta, OS için negatif prognostik faktörler olduğu görüldü. Ancak tüm evredeki KHAK hastalarında ortalama trombosit hacmi (MPV), MPV / trombosit oranı ve hemoglobinin sağkalım üzerinde hiçbir etkisi yoktu. Sonuç: Çalışmamızda tedavi almamış yaygın evredeki KHAK hastalarında NLR ve MCV’nin kötü prognozu belirlemede istatistiksel olarak anlamlı düzeyde etkili olduğu tesbit edilmiştir. Bu bulguları doğrulamak için büyük prospektif çalışmalar gerekmektedir.

Anahtar Kelime:

Konular: Genel ve Dahili Tıp

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

Byers LA, Rudin CM. Small Cell Lung Cancer: Where Do We Go From Here?. Cancer 2015; 121(5): 664-72.
Koinis F, Kotsakis A, Georgoulias V. Small cell lung cancer (SCLC): no treatment advances in recent years. Transl Lung Cancer Res 2016; 5(1): 39-50.
Mantovani A, Allavena P, Sica A, Ballkwill F. Cancer related inflammation. Nature 2008; 454(7203): 436-44.
Cools-Lartigue J, Spicer J, McDonald B, Gowing S, Chow S, Giannias B et al. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest 2013; 123(8): 3446–58.
Kang MH, Go SI, Song HN, Lee A, Kim SH, Kang JH et al. The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer. Br J Cancer 2014; 111(3): 452-60.
Pillay J, Kamp VM, Van Hoffen E, Visser T, Tak T, Lammers JW et al. A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1. J Clin Invest 2012; 122(1): 327–36.
Kaminska J, Kowalska M, Kotowicz B, Fuksiewicz M, Glogowski M, Wojcik E et al. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor.Oncology 2006; 70(2): 115-25.
Brown KM, Domin C, Aranha GV, Yong S, Shoup M. Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas. Am J Surg 2005; 189(3): 278-82.
Aoe K, Hiraki A, Ueoka H, Kiura K, Tabata M, Tanaka M et al. Thrombocytosis as a useful prognostic indicator in patients with lung cancer. Respiration 2004; 71(2):170–3.
Falanga A, Panova-Noeva M and Russo L. Procoagulant mechanisms in tumour cells. Best Pract Res Clin Haematol 2009; 22(1): 49-60.
Navalgund LG, Rossana C, Muench AJ, Johnson LF. Cell cycle regulation of thymidylate synthetase gene expression in cultured mouse fibroblasts. J Biol Chem 1980; 255(15): 7386-90.
Derenzini M, Montanaro L, Trere D, Chillà A, Tazzari PL, Dall'Olio F et al. Thymidylate synthase protein expression and activity are related to the cell proliferation rate in human cancer cell lines. Mol Pathol 2002; 55(5): 310-4.
Nakagawa T, Otake Y, Yanagihara K, Miyahara R, Ishikawa S, Fukushima M et al. Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC). Lung Cancer 2004; 43(2): 145-9.
Edler D, Hallström M, Johnston PG, Magnusson I, Ragnhammar P, Blomgren H. Thymidylate synthase expression:an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. Clinical Cancer Research. 2000; 6(4): 1378-84.
Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival. Journal of Clinical Oncology, Official Journal of the American Society of Clinical Oncology 1996; 14(1): 176-82.
Harpole DH Jr, Moore MB, Herndon JE, Aloia T, D'Amico TA, Sporn T et al.The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2001; 7(3): 562-9.
Sigmond J, Backus HHJ, Wouters D, Temmink OH, Jansen G, Peters GJ. Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochemical Pharmacology 2003; 66(3): 431-8.
Liu Q, Yu Z, Xiang Y, Wu N, Wu L, Xu B et al. Prognostic and predictive significance of thymidylate synthase protein expression in non-small cell lung cancer: a systematic review and meta-analysis. Cancer Biomark 2015; 15(1): 65-78.
Bremnes RM, Sundstrom S, Aaseb U, Kaasa S, Hatlevoll R, Aamdal S. Norweigian Lung Cancer Study Group The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer 2003; 39(3): 303-13.
Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 1990; 8(9):1563-74.
Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Groupexperience. J Clin Oncol 1991; 9(9):1618-26.
Fukui T, Itabashi M, Ishihara M, Hiyoshi Y, Kasajima M, Igawa S et al. Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer. BMC Cancer 2016;16: 197.
Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellularcarcinoma. Clin. Cancer Res 2014; 20(23): 6212-22.
Yin Y, Wang J, Wang X, Gu L, Pei H, Kuai S et al. Prognostic value of the neutrophil to lymphocyte ratio in lung cancer: A meta-analysis. Clinics 2015; 70(7): 524-30.
Inagaki N, Kibata K, Tamaki T, Shimizu T, Nomura S. Prognostic impact of the mean platelet volume/platelet count ratio in terms of survival in advanced non-smallcell lungcancer. Lung Cancer 2014; 83(1): 97-101.
Omar M, Tanriverdi O, Cokmert S, Oktay E, Yersal O, Pilancı KN et al. Turkish Descriptive Oncological Researches Group Role of increased mean platelet volume (MPV) and decreased MPV/platelet count ratio as poor prognostic factors in lung cancer. Clin Respir J 2017; 12(3): 922-9.
Wu G, Yao Y, Bai C, Zeng J, Shi D, Gu X et al. Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patients. Thoracic Cancer 2014; 6(3): 275–87.
Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O'Reilly DS et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 2011; 47(17): 2633-41.
Xie D, Marks R, Zhang M, Jiang G, Jatoi A, Garces YI et al. Nomograms Predict overall survival for patients with small-cell lung cancer incorporating pretreatment peripheral blood markers. J Thorac Oncol 2015; 10(8): 1213-20.
Hong X, Cui B, Wang M, Yang Z, Wang L, Xu Q. systemic ımmune-inflammation ındex, based on platelet counts and neutrophil-lymphocyte ratio, ıs useful for predicting prognosis in small cell lung cancer. Tohoku J Exp Med 2015; 236(4): 297-304.
Dirican N, Anar C, Atalay S, Öztürk Ö, Bircan HA, Çakır M et al. Effects on prognosis of hematologic parameters in patients with small cell lung cancer. Cukurova Medical Journal 2016; 41(2): 333-41.
Hong X, Cui B, Wang M, Yang Z, Wang L, Xu Q. Systemic Immune-inflammation Index, Based on Platelet Counts and Neutrophil-Lymphocyte Ratio, Is Useful for Predicting Prognosis in Small Cell Lung Cancer. Tohoku J Exp Med 2015; 236(4): 297-304.
Tuncel T, Ozgun A, Emirzeoglu L, Celik S, Bilgi O, Karagoz B. Mean Platelet Volume as a Prognostic Marker in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined Chemotherapy. Asian Pac J Cancer Prev 2014; 15 (15): 6421-3.
Kumagai S, Tokuno J, Ueda Y, Marumo S, Shoji T, Nishimura T et al.Prognostic significance of preoperative mean platelet volume in resected non-small-cell lung cancer. Molecular and Clinical Oncology 2015; 3(1): 197-201.

APA	oktay e, KESKIN O, EYİLER M, YERSAL Ö, Tanriverdi O, Nayir E, Dönmez Yalçın G, Meydan N (2019). WHICH HEMATOLOGIC PARAMETERS PREDICT SURVIVAL IN PATIENTS WITH SMALL CELL LUNG CANCER?. , 61 - 70.
Chicago	oktay esin,KESKIN Ozge,EYİLER M. Ferhat,YERSAL Özlem,Tanriverdi Ozgur,Nayir Erdinc,Dönmez Yalçın Gizem,Meydan Nezih WHICH HEMATOLOGIC PARAMETERS PREDICT SURVIVAL IN PATIENTS WITH SMALL CELL LUNG CANCER?. (2019): 61 - 70.
MLA	oktay esin,KESKIN Ozge,EYİLER M. Ferhat,YERSAL Özlem,Tanriverdi Ozgur,Nayir Erdinc,Dönmez Yalçın Gizem,Meydan Nezih WHICH HEMATOLOGIC PARAMETERS PREDICT SURVIVAL IN PATIENTS WITH SMALL CELL LUNG CANCER?. , 2019, ss.61 - 70.
AMA	oktay e,KESKIN O,EYİLER M,YERSAL Ö,Tanriverdi O,Nayir E,Dönmez Yalçın G,Meydan N WHICH HEMATOLOGIC PARAMETERS PREDICT SURVIVAL IN PATIENTS WITH SMALL CELL LUNG CANCER?. . 2019; 61 - 70.
Vancouver	oktay e,KESKIN O,EYİLER M,YERSAL Ö,Tanriverdi O,Nayir E,Dönmez Yalçın G,Meydan N WHICH HEMATOLOGIC PARAMETERS PREDICT SURVIVAL IN PATIENTS WITH SMALL CELL LUNG CANCER?. . 2019; 61 - 70.
IEEE	oktay e,KESKIN O,EYİLER M,YERSAL Ö,Tanriverdi O,Nayir E,Dönmez Yalçın G,Meydan N "WHICH HEMATOLOGIC PARAMETERS PREDICT SURVIVAL IN PATIENTS WITH SMALL CELL LUNG CANCER?." , ss.61 - 70, 2019.
ISNAD	oktay, esin vd. "WHICH HEMATOLOGIC PARAMETERS PREDICT SURVIVAL IN PATIENTS WITH SMALL CELL LUNG CANCER?". (2019), 61-70.

APA	oktay e, KESKIN O, EYİLER M, YERSAL Ö, Tanriverdi O, Nayir E, Dönmez Yalçın G, Meydan N (2019). WHICH HEMATOLOGIC PARAMETERS PREDICT SURVIVAL IN PATIENTS WITH SMALL CELL LUNG CANCER?. İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi, 23(1), 61 - 70.
Chicago	oktay esin,KESKIN Ozge,EYİLER M. Ferhat,YERSAL Özlem,Tanriverdi Ozgur,Nayir Erdinc,Dönmez Yalçın Gizem,Meydan Nezih WHICH HEMATOLOGIC PARAMETERS PREDICT SURVIVAL IN PATIENTS WITH SMALL CELL LUNG CANCER?. İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi 23, no.1 (2019): 61 - 70.
MLA	oktay esin,KESKIN Ozge,EYİLER M. Ferhat,YERSAL Özlem,Tanriverdi Ozgur,Nayir Erdinc,Dönmez Yalçın Gizem,Meydan Nezih WHICH HEMATOLOGIC PARAMETERS PREDICT SURVIVAL IN PATIENTS WITH SMALL CELL LUNG CANCER?. İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi, vol.23, no.1, 2019, ss.61 - 70.
AMA	oktay e,KESKIN O,EYİLER M,YERSAL Ö,Tanriverdi O,Nayir E,Dönmez Yalçın G,Meydan N WHICH HEMATOLOGIC PARAMETERS PREDICT SURVIVAL IN PATIENTS WITH SMALL CELL LUNG CANCER?. İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi. 2019; 23(1): 61 - 70.
Vancouver	oktay e,KESKIN O,EYİLER M,YERSAL Ö,Tanriverdi O,Nayir E,Dönmez Yalçın G,Meydan N WHICH HEMATOLOGIC PARAMETERS PREDICT SURVIVAL IN PATIENTS WITH SMALL CELL LUNG CANCER?. İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi. 2019; 23(1): 61 - 70.
IEEE	oktay e,KESKIN O,EYİLER M,YERSAL Ö,Tanriverdi O,Nayir E,Dönmez Yalçın G,Meydan N "WHICH HEMATOLOGIC PARAMETERS PREDICT SURVIVAL IN PATIENTS WITH SMALL CELL LUNG CANCER?." İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi, 23, ss.61 - 70, 2019.
ISNAD	oktay, esin vd. "WHICH HEMATOLOGIC PARAMETERS PREDICT SURVIVAL IN PATIENTS WITH SMALL CELL LUNG CANCER?". İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi 23/1 (2019), 61-70.